Study of Combined Anticoagulant and Antiplatelet Treatment After Iliac Vein Stenting for Deep Vein Thrombosis

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining anticoagulant and antiplatelet therapy to keep the iliac vein open one year after stenting in patients with acute proximal deep vein thrombosis DVT and iliac vein narrowing. This single-arm, open-label study involves 172 adults diagnosed with these conditions who have undergone percutaneous mechanical thrombectomy and iliac vein stenting. The study is conducted across multiple centers in Zhejiang Province, China. Participants will receive rivaroxaban 20 mg once daily for six months along with aspirin 100 mg once daily indefinitely after the stent placement. The study lasts 12 months, with follow-up visits at 3, 6, and 12 months to monitor treatment effects and safety. Evaluations include vein patency, bleeding events, post-thrombotic syndrome severity, and DVT recurrence rates. During the study, participants will have regular assessments to document efficacy and safety outcomes, including clinical evaluations and monitoring for bleeding or other complications. Data collected throughout the 12-month period will be analyzed to understand the combination therapys impact on maintaining vein openness and patient safety after iliac vein stenting.

Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting